Clay Siegall: A leader in cancer research

Cancer is among the top leading causes of death around the world. In fact, according the National Cancer Institute ” in 2016, an estimated 1,685,210 new cases of cancer will be diagnosed and 595,690 people will die from the disease.” They also state in a 2014 study that, ” an estimated 15,780 children and adolescents aged 0-19 were diagnosed with cancer and 1,960 died of this disease.” While these statistics seem scary, there’s researchers developing new treatments and searching for a cure. Continue reading to learn about a company that takes leadership in this field.

Clay Siegall, co-founder, CEO and president of Seattle Genetics, is actively seeking a cure for cancer. Under his leadership, Seattle Genetics has developed an Antibody Drug Conjugate (ADC’s). These ADC’s selectively kill off cancer cells while leaving healthy cells alive. In addition to ADC’s, they’re expanding the use of Adcetrics to diseases beyond cancer.

Siegall’s passion for helping others and in vigorous research practices, puts Seattle Genetics in the leadership position for the cancer research community. Clay Siegall, has taken this leadership, going in with the mindset of finding an end to this illness.

Starting his career as a scientist, Mr. Siegall worked for Bristol-Myer Squibb (a pharmaceutical company) and the National Cancer Institute. Mr. Siegall serves on the Board of Directors for several pharmaceutical companies such as, Alder Pharmaceuticals, Mirna Therapies, Ultragenyx, and Seattle Genetics.

After founding Seattle Genetics in 1998, Mr. Siegall lead the company into the leadership role for cancer research. He was driven by his desire to end this illness that claims the lives of hundreds of thousands every year.

Clay Siegall, Ph. D. – CEO, President, Cancer Fighter

Clay Siegall founded Seattle Genetics, Inc. in 1998. It is a pharmaceuticals and biotechnology Corporation specializing in treatment for many various cancer diseases. Seattle Genetics, Inc. is located in Bothell, Washington’s Puget Sound area, and is Washington State’s largest biotech Corporation.

Their inaugural, commercialized drug, Adcetris, is being considered for use in more cancer treatments than the current 70 various lymphoma types undergoing trials. Particularly, Seattle Genetics is directing an advanced trial that will utilize Adcetris as an up-front treatment for newly diagnosed or otherwise untreated patients with Hodgkin Lymphoma.

Adcetris’ main use, so far, is to combat lymphomas. It has brought in $226 million in sales in the U.S. and Canada in the previous year and is set to increase that amount, in 2016, to approximately $255 to $275 million. Takeda Pharmaceuticals, Seattle Genetics Partner, handles sales outside of Canada and the U.S. Antibody-based Adcetris is just the first of 12 other drugs being developed by Seattle Genetics. One of these, referred to as 33A, is a drug for treatment of myeloid leukemia. They also have a breast cancer drug and two other drugs for the treatment of bladder cancer. They hope to get these new drugs into use this year.

Seattle Genetics, Inc. also plans a large-scale hiring event. Though it already employs more than 800 people, there are plans this year to hire an additional 100 employees here and another 20 in their Switzerland office. Most new hires will be positioned in “operations” rather than research.

Clay Siegall earned BS and Zoology Degrees at the University of Maryland and a Ph.D. and Genetics degree at the George Washington University, where he was Alumnus of The Year for Natural Science, Math, and Computer. Mr. Siegall has been the Co-Founder, President, CEO, and Chairman of the Board of Seattle Genetics, Inc., since 1998.

Mr. Siegall has also been on Alder Biopharmaceuticals Board of Directors since 2006, and a Board Member of Mirna Therapeutics since 2013. He is also on the Board of Directors at Ultragenyx Pharmaceuticals, which markets new products for treating rare and extremely rare diseases, since 2014.